22211 West Interstate 10
Suite 1206
San Antonio, TX 78257
United States
210 698 5334
https://www.bioaffinitytech.com
Settore/i: Healthcare
Settore: Diagnostics & Research
Impiegati a tempo pieno:
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Steven Girgenti | Founder & Executive Chairman of the Board | 113,75k | N/D | 1946 |
Ms. Maria Zannes J.D. | Founder, President, CEO & Director | 299,17k | N/D | 1956 |
Mr. Michael Dougherty CPA, M.B.A. | VP & CFO | 238,92k | N/D | 1979 |
Mr. Xavier T. Reveles M.S. | Chief Operating Officer | N/D | N/D | 1970 |
Dr. Vivienne I. Rebel M.D., Ph.D. | Executive VP and Chief Medical & Science Officer | 238,39k | N/D | 1966 |
Mr. Timothy P. Zannes J.D. | Executive VP, Secretary & General Counsel | N/D | N/D | 1953 |
Ms. Julie Anne Overton | Director of Communications | N/D | N/D | N/D |
Mr. Dallas J. Coleman | National Director of Sales | N/D | N/D | N/D |
Dr. William Bauta Ph.D. | Senior Vice President of Therapeutics | N/D | N/D | N/D |
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
L'ISS Governance QualityScore di bioAffinity Technologies, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.